Royalty Pharma (RPRX) Loans and Notes Receivables (2019 - 2025)
Royalty Pharma (RPRX) has disclosed Loans and Notes Receivables for 7 consecutive years, with $854.4 million as the latest value for Q4 2025.
- Quarterly Loans and Notes Receivables rose 9.01% to $854.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $854.4 million through Dec 2025, up 9.01% year-over-year, with the annual reading at $854.4 million for FY2025, 9.01% up from the prior year.
- Loans and Notes Receivables hit $854.4 million in Q4 2025 for Royalty Pharma, down from $860.1 million in the prior quarter.
- In the past five years, Loans and Notes Receivables ranged from a high of $860.1 million in Q3 2025 to a low of $522.4 million in Q1 2021.
- Historically, Loans and Notes Receivables has averaged $697.3 million across 5 years, with a median of $703.9 million in 2022.
- Biggest five-year swings in Loans and Notes Receivables: grew 16.58% in 2022 and later rose 2.77% in 2024.
- Year by year, Loans and Notes Receivables stood at $614.4 million in 2021, then rose by 12.53% to $691.3 million in 2022, then increased by 6.82% to $738.4 million in 2023, then rose by 6.14% to $783.8 million in 2024, then increased by 9.01% to $854.4 million in 2025.
- Business Quant data shows Loans and Notes Receivables for RPRX at $854.4 million in Q4 2025, $860.1 million in Q3 2025, and $842.9 million in Q2 2025.